Incontinence medication response relates to the female urinary microbiota.
Incontinence medication response relates to the female urinary microbiota.
复制标题
DOI：
10.1007/s00192-015-2847-x
复制
发表时间：
2016-05
影响因子：
1.8
通讯作者：
Wolfe, Alan J.
中科院分区：
文献类型：
--
作者：
Thomas-White, Krystal J.;Hilt, Evann E.;Fok, Cynthia;Pearce, Meghan M.;Mueller, Elizabeth R.;Kliethermes, Stephanie;Jacobs, Kristin;Zilliox, Michael J.;Brincat, Cynthia;Price, Travis K.;Kuffel, Gina;Schreckenberger, Paul;Gai, Xiaowu;Brubaker, Linda;Wolfe, Alan J.
许多成年女性体内都有常驻尿细菌（尿微生物组/微生物群）。在受尿急尿失禁 (UUI) 影响的成年女性中，泌尿微生物组/微生物群的病因和/或治疗作用仍不清楚。微生物组/微生物群特征将与口服 UUI 药物的临床相关治疗反应相关。在三级医疗保健系统中招募了开始口服药物治疗 UUI 的成年女性和未受影响的女性作为对照组。所有参与者都提供了基线临床数据和尿液。患有 UUI 的女性接受 5 毫克索利那新治疗，如果 4 周后 UUI 症状控制不充分，剂量可能会增加至 10 毫克。在 4 周和 12 周时从患有 UUI 的女性中收集了额外的数据和尿液样本。通过 16S rRNA 基因测序和增强定量尿液培养对样本进行评估。主要结局是通过经过验证的患者整体症状控制 (PGSC) 调查问卷测量的治疗反应。临床相关 UUI 症状控制被定义为 PGSC 得分为 4 或 5。患有和未患有 UUI 的女性的尿液微生物组/微生物群的多样性和组成在基线时有所不同。患有 UUI 的女性有更多的细菌和更多样化的微生物组/微生物群。 UUI 参与者对索利那新的临床反应与基线微生物组/微生物群相关，反应者在基线时更有可能拥有较少的细菌和较少多样性的群落。无反应者的群落更加多样化，其中通常包括反应者中通常不存在的细菌。了解个人的尿液微生物组/微生物群可能有助于完善 UUI 治疗。 DNA 测序和扩大尿液培养等补充工具提供了与该成年女性群体中 UUI 失禁状态和 UUI 治疗反应相关的细菌信息。成年女性的个体尿液微生物组/微生物群因 UUI 的存在而异。在接受口服 UUI 药物治疗的女性中，微生物群与 UUI 治疗反应相关。
Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. Microbiome/microbiota characteristics will relate to clinically relevant treatment response to oral UUI medication. Adult women initiating oral medication treatment for UUI and a comparator group of unaffected women were recruited in a tertiary care health care system. All participants provided baseline clinical data and urine. Women with UUI were given 5mg solifenacin with potential dose escalation to 10mg for inadequate UUI symptoms control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed by 16S rRNA gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC. The diversity and composition of the urinary microbiome/microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria and a less diverse community at baseline. Non-responders had a more diverse community that often included bacteria not typically found in responders. Knowledge of an individual’s urinary microbiome/microbiota may help refine UUI treatment. Complementary tools, DNA sequencing and expanded urine culture, provide information about bacteria that appear related to UUI incontinence status and UUI treatment response in this population of adult women. Adult womens’ individual urinary microbiome/microbiota differ based on presence of UUI. The microbiota relate to UUI treatment response in women treated with oral UUI medication.
登录
查看更多内容
影响因子：
23.4
作者：
Wolfe AJ;Brubaker L
通讯作者：
Brubaker L
影响因子：
5.7
作者：
Lewis DA;Brown R;Williams J;White P;Jacobson SK;Marchesi JR;Drake MJ
通讯作者：
Drake MJ
影响因子：
7.4
作者：
Fouts DE;Pieper R;Szpakowski S;Pohl H;Knoblach S;Suh MJ;Huang ST;Ljungberg I;Sprague BM;Lucas SK;Torralba M;Nelson KE;Groah SL
通讯作者：
Groah SL
影响因子：
4.4
作者：
Schloss, Patrick D.;Westcott, Sarah L.;Weber, Carolyn F.
通讯作者：
Weber, Carolyn F.
影响因子：
3.5
作者：
Coyne, K;Revicki, D;Abrams, P
通讯作者：
Abrams, P